REFERENCES
- Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human im-munodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003;37:113–128.
- Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579–588.
- Baxter JD, Mayers DL, Wentworth DN, et al. A random-ized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000;14:F83–93.
- Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002;16: 727–736.
- Swanstrom R, Bosch RJ, Katzenstein D, et al. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-in-fected subjects. J Infect Dis. 2004;190:886–893.
- Haubrich RH, Kemper CA, Hellmann NS, et al. A random-ized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS. 2005;19:295–302.
- Whitcomb JM, Huang W, Limoli K, et al. Hypersuscepti-bility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS. 2002;16:F41–47.
- Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bach-eler L, Albrecht MA. Phenotypic susceptibility and virologi-cal outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS. 2003;17:821–830.
- Haubrich RH, Kemper CA, Hellmann NS, et al. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002;16:F33–40.
- Gulick RM, Hu XJ, Fiscus SA, et al. Randomized study of sa-quinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182:1375–1384.
- Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phe-notypic drug susceptibility assay for human immuno-deficiency virus type 1. Antimicrob Agents Chemother 2000;44:920–928.
- Bosch RJ, Downey GF, Katzenstein DA, Hellmann N, Bach-eler L, Albrecht MA. Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz. AIDS. 2003;17:2395–2396.